Hong Cheol Am, Nam Yoon Sung
1. Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST), 291 Daehak-ro, Yuseong-gu, Daejeon, 305-701, Republic of Korea;
1. Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST), 291 Daehak-ro, Yuseong-gu, Daejeon, 305-701, Republic of Korea; ; 2. Department of Materials Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), 291 Daehak-ro, Yuseong-gu, Daejeon, 305-701, Republic of Korea; ; 3. KAIST Institute for NanoCentury and BioCentury, Korea Advanced Institute of Science and Technology (KAIST), 291 Daehak-ro, Yuseong-gu, Daejeon, 305-701, Republic of Korea.
Theranostics. 2014 Sep 19;4(12):1211-32. doi: 10.7150/thno.8491. eCollection 2014.
Small interfering RNA (siRNA) has proved to be a powerful tool for target-specific gene silencing via RNA interference (RNAi). Its ability to control targeted gene expression gives new hope to gene therapy as a treatment for cancers and genetic diseases. However, siRNA shows poor pharmacological properties, such as low serum stability, off-targeting, and innate immune responses, which present a significant challenge for clinical applications. In addition, siRNA cannot cross the cell membrane for RNAi activity because of its anionic property and stiff structure. Therefore, the development of a safe, stable, and efficient system for the delivery of siRNA therapeutics into the cytoplasm of targeted cells is crucial. Several nanoparticle platforms for siRNA delivery have been developed to overcome the major hurdles facing the therapeutic uses of siRNA. This review covers a broad spectrum of non-viral siRNA delivery systems developed for enhanced cellular uptake and targeted gene silencing in vitro and in vivo and discusses their characteristics and opportunities for clinical applications of therapeutic siRNA.
小干扰RNA(siRNA)已被证明是一种通过RNA干扰(RNAi)实现靶向基因沉默的强大工具。其控制靶向基因表达的能力为基因治疗作为癌症和遗传疾病的治疗方法带来了新的希望。然而,siRNA表现出较差的药理学特性,如血清稳定性低、脱靶效应和先天性免疫反应,这对临床应用构成了重大挑战。此外,由于其阴离子特性和刚性结构,siRNA无法穿过细胞膜进行RNAi活性。因此,开发一种安全、稳定且高效的系统,将siRNA治疗剂递送至靶细胞的细胞质中至关重要。已经开发了几种用于siRNA递送的纳米颗粒平台,以克服siRNA治疗应用面临的主要障碍。本综述涵盖了为增强体外和体内细胞摄取及靶向基因沉默而开发的广泛的非病毒siRNA递送系统,并讨论了它们的特性以及治疗性siRNA临床应用的机会。